Previous 10 | Next 10 |
Annualized recurring revenue (“ARR”) of $807 million, an increase of 11% year-over-year Total revenue of $205 million, up 12% year-over-year; Product subscriptions revenue of $197 million, up 13% year-over-year GAAP operating income of $11 million; Non-GAAP operating income ...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
2024-05-04 01:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-25 18:00:04 ET Patrick Colville from Scotiabank issued a price target of $46.00 for RPD on 2024-04-25 16:20:00. The adjusted price target was set to $46.00. At the time of the announcement, RPD was trading at $45.85. The overall price target consensus is at $93.8...
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m...
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to shareholders of record at the clos...
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leader in extended risk and threat detection, today announced that the company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, after the financial markets close. The company will ...
2024-04-04 11:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a leader in extended risk and threat detection, today announced the winners of its 2024 Partner of the Year Awards. “Rapid7’s Partner of the Year Awards program is an important way for us to recognize the...
2024-03-28 01:54:09 ET Summary Rapid7's stock has underperformed and been volatile, currently down -10.3% YTD. The company's fundamentals are decent, with non-GAAP profitability and operating cash flow improving. Rapid7 aims to focus on profitable growth in 2024, driven by IT ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...
2024-07-09 22:15:01 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for RPD on July 9, 2024 09:06PM ET. The previous analyst recommendation was Equal-Weight. RPD was trading at $39.72 at issue of the analyst recommendation. The overall analyst consensus : BU...